

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors, and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

For all that apply, please note where in the manuscript the required information is provided.

Materials:

Newly created materials	indicate where provided: page no/section/legend)	n/a
The manuscript includes a dedicated "materials availability statement" providing transparent disclosure about availability of newly created materials including details on how materials can be accessed and describing any restrictions on access.		X
Antibodies	indicate where provided: page no/section/legend)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID , if available.		X
DNA and RNA sequences	indicate where provided: page no/section/legend)	n/a
Short novel DNA or RNA including primers, probes: Sequences should be included or deposited in a public repository.		X
Cell materials	indicate where provided: page no/section/legend)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID.		X
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		X
Experimental animals	indicate where provided: page no/section/legend)	n/a
Laboratory animals or Model organisms: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID.		X
Animal observed in or captured from the field: Provide species, sex, and age where possible.		X
Plants and microbes	indicate where provided: page no/section/legend)	n/a
Plants: provide species and strain, ecotype and cultivar where relevant, unique accession number if available, and source (including location for collected wild specimens).		X
Microbes: provide species and strain, unique accession number if available, and source.		X
Human research participants	indicate where provided: page no/section/legend) or state if these demographics were not collected	n/a
If collected and within the bounds of privacy constraints report on age, sex and gender or ethnicity for all study participants.		X

Design:

Study protocol	indicate where provided: page no/section/legend)	n/a
If study protocol has been pre-registered, provide DOI. For clinical trials, provide the trial registration number OR cite DOI.		X
Laboratory protocol	indicate where provided: page no/section/legend)	n/a
Provide DOI OR other citation details if detailed step-by-step protocols are available.		X
Experimental study design (statistics details)		
For in vivo studies: State whether and how the following have been done	indicate where provided: page no/section/legend. If it could have been done, but was not, write not done	n/a
Sample size determination		X
Randomisation		X
Blinding		X
Inclusion/exclusion criteria		X
Sample definition and in-laboratory replication	indicate where provided: page no/section/legend	n/a
State number of times the experiment was replicated in laboratory.		X
Define whether data describe technical or biological replicates.		X
Ethics	indicate where provided: page no/section/legend	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		X
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		X
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		X
Dual Use Research of Concern (DURC)	indicate where provided: page no/section/legend	n/a
If study is subject to dual use research of concern regulations, state the authority granting approval and reference number for the regulatory approval.		X

Analysis:

Attrition	indicate where provided: page no/section/legend	n/a
Describe whether exclusion criteria were preestablished. Report if sample or data points were omitted from analysis. If yes report if this was due to attrition or intentional exclusion and provide justification.	Exclusion criteria regarding genome sequences is in the Results section of the main text (paragraphs 1–3) and in the following section of the Materials and Methods: <i>Sequence data</i> .	
Statistics	indicate where provided: page no/section/legend	n/a
Describe statistical tests used and justify choice of tests.	Statistical tests are described in the following sections of the Material and Methods: <i>Quantifying the support for ancestral haplotypes</i> , <i>Quantifying the support for two introductions against a single introduction</i> . The statistical tests used are Bayes factor analyses to quantify the support for specific ancestral haplotypes and whether there were multiple introductions of SARS-CoV-2.	
Data availability	indicate where provided: page no/section/legend	n/a
For newly created and reused datasets, the manuscript includes a data availability statement that provides details for access or notes restrictions on access.	Data availability statement is in the Acknowledgements section of the main manuscript.	
If newly created datasets are publicly available, provide accession number in repository OR DOI OR URL and licensing details where available.	The raw data for EPI_ISL_413017 and EPI_ISL_462306 are available at https://www.ncbi.nlm.nih.gov/sra , with project IDs PRJNA806767 and PRJNA802993. The simulated data will be provided on Data Dryad, as cited in the Acknowledgements. The ancestral state reconstruction posterior probability is available in Data S3.	
If reused data is publicly available provide accession number in repository OR DOI OR URL, OR citation.	Accession numbers for previously published genomes are available in Data S1 and S2.	X
Code availability	indicate where provided: page no/section/legend	n/a
For all newly generated custom computer code/software/mathematical algorithm or re-used code essential for replicating the main findings of the study, the manuscript includes a data availability statement that provides details for access or notes restrictions.	Code for this manuscript is provided on Zenodo, as cited in the Acknowledgements.	
If newly generated code is publicly available, provide accession number in repository, OR DOI OR URL and licensing details where available. State any restrictions on code availability or accessibility.	Code for this manuscript is provided on Zenodo, as cited in the Acknowledgements.	
If reused code is publicly available provide accession number in repository OR DOI OR URL, OR citation.		X

Reporting

MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.

Adherence to community standards	indicate where provided: page no/section/legend	n/a
State if relevant guidelines (e.g., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (e.g., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.		X